Understanding the idiopathic pulmonary fibrosis patient community [whitepaper]

It is estimated that 50,000 individuals are diagnosed with Idiopathic pulmonary fibrosis (IPF) each year in the United States, and 140,000 are estimated to live with the disease. Individuals who live with IPF often experience the disease with varying degrees of severity, and it is this variability that makes IPF particularly difficult to treat.

Because IPF has no known cause or cure, there is a clear need for continued research. In this whitepaper, we’re sharing informative IPF patient data regarding demographics, treatment history, and more — these patients have already raised their hands to participate in research, and through this data, we are sharing insights that can help researchers design impactful studies. To see what we discovered and how it can impact clinical trial enrollment, fill out the form to get your copy of the whitepaper.